Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bristol Myers Squibb : Myers says shareholders vote to approve Celgene takeover

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2019 | 01:21pm EDT
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage

NEW YORK (Reuters) - Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

The company said investors holding 75.7 percent of the shares voted were in favor of the deal in a preliminary count.

"We, from a management perspective, from a board perspective, truly believe this is the right transaction for us," Bristol-Myers Chief Executive Giovanni Caforio told reporters after the vote.

"The focus is on us right now to execute on the integration and then deliver the value of the combined portfolio, to confirm that the new company will deliver significant value for shareholders," he said.

Celgene said separately in a statement that its shareholders representing more than 70 percent of its shares outstanding who were entitled to vote, voted in favor of the transaction.

The companies expect the deal to close in the third quarter.

Bristol-Myers announced in early January that it planned to buy Celgene in a cash and stock transaction to bring together companies that specialize in oncology and cardiovascular drugs in what would be the largest pharmaceutical industry merger ever.

The New York-based drugmaker has said the combined company will have six drugs with expected near-term launches - five from the Celgene pipeline - representing over $15 billion in annual revenue potential - as well as strong early-stage experimental assets.

But Starboard and the company's second largest shareholder, Wellington Management, opposed the deal.

Starboard called it "poorly conceived and ill-advised," and criticized Bristol-Myers' management and board, suggesting they would not be able to successfully execute a risky deal.

Starboard abandoned the campaign against the deal late last month after proxy advisory firms recommended investors support it.

Bristol-Myers said during a shareholders meeting that it does not expect changes to its dividend policy after the acquisition.

Bristol-Myers shares fell 50 cents, or 1.1 percent, to $45.59 in Friday afternoon trading on the New York Stock Exchange. Celgene shares fell 9 cents to $94.14 on the Nasdaq.

(Reporting by Michael Erman and Svea Herbst-Bayliss, writing by Caroline Humer; Editing by Chizu Nomiyama and Bill Berkrot)

By Michael Erman and Svea Herbst-Bayliss

Stocks treated in this article : Celgene Corporation, Bristol-Myers Squibb Company
Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 1.77% 45.39 Delayed Quote.-12.81%
CELGENE CORPORATION 0.84% 93.9 Delayed Quote.45.31%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
11:42aBRISTOL MYERS SQUIBB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
08:07aBRISTOL MYERS SQUIBB CO : Results of Operations and Financial Condition, Financi..
AQ
07:16aBristol's Opdivo, Eliquis Lift Results Ahead of Celgene Deal
DJ
07:11aBRISTOL MYERS SQUIBB : Myers profit slightly tops Wall Street view on blood thin..
RE
07:10aBRISTOL-MYERS : 1Q Earnings Snapshot
AQ
07:00aBRISTOL MYERS SQUIBB : Reports First Quarter Financial Results
BU
04/17BRISTOL MYERS SQUIBB CO : Other Events, Financial Statements and Exhibits (form ..
AQ
04/17BRISTOL-MYERS SQUIBB COMPANY : Announces Commencement of Exchange Offers and Con..
BU
04/16BRISTOL MYERS SQUIBB : FameWave Announces Clinical Collaboration with Bristol My..
AQ
04/16BRISTOL MYERS SQUIBB : Thumbs-up on $74B BMS-Celgene deal ends months of activis..
AQ
More news
Financials ($)
Sales 2019 24 007 M
EBIT 2019 6 957 M
Net income 2019 6 759 M
Finance 2019 4 994 M
Yield 2019 3,62%
P/E ratio 2019 11,21
P/E ratio 2020 10,66
EV / Sales 2019 2,88x
EV / Sales 2020 2,61x
Capitalization 74 051 M
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 57,9 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-12.81%74 051
JOHNSON & JOHNSON8.41%372 522
ROCHE HOLDING LTD.9.68%227 039
PFIZER-9.69%218 852
NOVARTIS7.44%195 750
MERCK AND COMPANY-2.20%192 697